Figitumumab (CP-751871) is a fully human monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF1R) with high potency. By inhibiting the binding of IGF1 to IGF1R, figitumumab achieves an IC50 value of 1.8 nM, effectively blocking the receptor's activation [1].